Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label Study of Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

NCT03397394 is registered in ClinicalTrials.gov with pharmaand GmbH as lead sponsor.

NCT NCT03397394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03397394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label Study of Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Lead sponsor
pharmaand GmbH
Phase
Phase 2
Overall status
Terminated
Start date
June 1, 2018
Completion date
January 15, 2020
Enrollment
97 (actual)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, metastatic urothelial carcinoma, muscle invasive bladder cancer, renal pelvis carcinoma, ureter carcinoma, urethra carcinoma, urinary bladder carcinoma, urothelial carcinoma